The Jab from The Economist

The Economist
The Jab from The Economist

The Economist unlocks the science, data and politics behind the most ambitious inoculation programme the world has ever seen. Alok Jha, The Economist’s science correspondent, hosts with Natasha Loder, our health-policy editor. Each week our reporters and data journalists join them in conversation, along with scientists around the world. Sign up for Economist Podcasts+ at www.economist.com/podcastsplus If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription.

  1. The Jab: How well will vaccines work?

    ÉPISODE 1 • ABONNÉS UNIQUEMENT

    The Jab: How well will vaccines work?

    The race between infections and injections is in its most crucial phase. What life is like on the other side of the pandemic depends on three things: how well vaccines work, whether there are enough and how many people take them. Michael Osterholm, an epidemiologist who has advised President Biden, tells us the world stands at an inflection point. After getting his jab in Jerusalem, our correspondent there says the vision of the future Israel offers other countries is not as rosy as it first seemed. James Fransham from The Economist data team unpicks the vaccination numbers so far.  Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Edward Carr, The Economist's deputy editor, joins them. For full access to The Economist’s print, digital and audio editions subscribe here: economist.com/thejabpod Subscribe to our new weekly science newsletter at economist.com/simplyscience and data newsletter at www.economist.com/offthecharts Hosted on Acast. See acast.com/privacy for more information.

    40 min
  2. The Jab: Are the vaccines effective enough?

    ÉPISODE 2 • ABONNÉS UNIQUEMENT

    The Jab: Are the vaccines effective enough?

    Three vaccines have been approved by stringent regulators. Ten are being used in one or more countries. How do they work and are they effective enough against new variants of the coronavirus? Sarah Gilbert, inventor of the Oxford/Astrazeneca vaccine, tells us adapting to new variants should be easy. The Economist’s Beijing bureau chief David Rennie reports from China, which faces a huge test of its homegrown vaccine technology as it tries to re-open. James Fransham from our data team on how far the variants have spread. Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Slavea Chankova, The Economist's health-care correspondent, joins them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod and sign up for our new weekly science newsletter at economist.com/simplyscience Hosted on Acast. See acast.com/privacy for more information.

    36 min
  3. The Jab: Will there be enough vaccines?

    ÉPISODE 3 • ABONNÉS UNIQUEMENT

    The Jab: Will there be enough vaccines?

    It is one thing to design and test covid-19 vaccines. It is another to make them at sufficient scale to generate the billions of doses needed to vaccinate the world’s population. How are the vaccines produced, why is production so variable and will it meet demand this year? We speak to Adar Poonawalla, CEO of the Serum Institute of India, the world's biggest supplier of vaccines. The Economist’s technology correspondent Hal Hodson explains why some vaccines take longer to produce than others. James Fransham from our data team discusses when supply will meet demand. Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, The Economist's briefing editor, joins them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts Hosted on Acast. See acast.com/privacy for more information.

    40 min
  4. The Jab: Trial and error?

    ÉPISODE 4 • ABONNÉS UNIQUEMENT

    The Jab: Trial and error?

    Large scale covid-19 vaccine trials have taken place at exceptional speed with unprecedented scrutiny. How do they work? And why are the results so politically charged?  We speak to Andrew Catchpole, lead scientist on the first trial to infect volunteers with the virus intentionally. Jason Palmer, presenter of The Intelligence, assists in a trial.  Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Slavea Chankova, The Economist's health-care correspondent, and James Fransham, from our data team, join them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts Hosted on Acast. See acast.com/privacy for more information.

    37 min
  5. The Jab: How will behaviour change?

    ÉPISODE 5 • ABONNÉS UNIQUEMENT

    The Jab: How will behaviour change?

    The world has stumbled through the pandemic by nationalising risk. In heavily infected countries citizens have been ordered to stay home for weeks at a time. As covid-19 vaccination programmes spread, governments must gradually restore choice to the individual. How? We speak to Ozlem Tureci and Ugur Sahin—the couple who co-founded BioNTech which created the first covid-19 vaccine to get regulatory approval.  Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. The Economist's deputy editor Edward Carr, Europe correspondent Vendeline Von Bredow and Dan Rosenheck from our data team join them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts Hosted on Acast. See acast.com/privacy for more information.

    40 min
  6. The Jab: Will America do better than Europe?

    ÉPISODE 6 • ABONNÉS UNIQUEMENT

    The Jab: Will America do better than Europe?

    The EU was slow to roll out covid-19 vaccines, then destroyed confidence in the Astrazeneca vaccine and is now embroiled in a row over supplies. Will America avoid Europe's pitfalls? Dr Anthony Fauci, chief medical adviser to President Biden, explains vaccination progress in America, the plateau of new infections and his plan to combat new variants. Also, how does America's federal system affect the vaccination programme? Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Edward Carr, The Economist's deputy editor and our New York correspondent Rosemarie Ward join them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts Hosted on Acast. See acast.com/privacy for more information.

    45 min

  7. ÉPISODE 7 • ABONNÉS UNIQUEMENT

    The Jab: How will science benefit?

    The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?    Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.    Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them.   For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts   Hosted on Acast. See acast.com/privacy for more information.

    40 min
  8. The Jab: Can distribution be fair?

    ÉPISODE 8 • ABONNÉS UNIQUEMENT

    The Jab: Can distribution be fair?

    More than a billion doses of covid-19 vaccine have been made. Now comes the hard part: ensuring every country in the world has access to them. Can distribution be made more equitable?    Alok Jha and Natasha Loder are joined by Edward Carr, The Economist’s deputy editor, and Sondre Solstad, senior data journalist.   With Seth Berkley of GAVI, the Vaccine Alliance, and John Nkengasong, director of the Africa Centres for Disease Control and Prevention.   For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts  Hosted on Acast. See acast.com/privacy for more information.

    40 min
Tout afficher (21)

Bande-annonce

Podcasts avec bonus en cas d’abonnement

  • A sophisticated, predatory, multi-billion dollar industry is emerging from the shadows. It already rivals the size of the illicit drug trade. And it’s about to get bigger and much more powerful.  The Economist’s Sue-Lin Wong follows a trail that starts with the collapse of a bank in rural Kansas to uncover a global, underground scam economy built around human trafficking, corruption and money laundering. Can it be stopped? To listen to the full series subscribe to Economist Podcasts+.

    • 4,8 (134)
    • AFFAIRES

  • Every weekday our global network of correspondents makes sense of the stories beneath the headlines. We bring you surprising trends and tales from around the world, current affairs, business and finance — as well as science and technology.   Hosted on Acast. See acast.com/privacy for more information.

    • 4,3 (3673)
    • ACTUALITÉS

  • Get a daily burst of illumination from The Economist’s worldwide network of correspondents. Our reporters dig past the headlines to get to the stories beneath—and to stories that aren’t making headlines, but should be. A unique perspective on the issues and events shaping your world. Sign up for Economist Podcasts+ at http://www.economist.com/podcastsplus-intelligence. If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription. For more information about Economist Podcasts+, including how to get access, please visit our FAQs page at https://myaccount.economist.com/s/article/What-is-Economist-Podcasts

    • 4,5 (2343)
    • ACTUS DU JOUR

  • The World in Brief tells you what’s on the global agenda in the coming day, what to look out for in business, finance and politics and, most importantly, what to make of it. Economist Podcasts+ subscribers and digital subscribers to The Economist should log in at economist.com/audio/podcasts/the-world-in-brief for access to the full World in Brief. Sign up for Economist Podcasts+ here: www.economist.com/podcastsplus-worldinbrief. For more information about Economist Podcasts+, including how to get access, please visit our FAQs page here https://myaccount.economist.com/s/article/What-is-Economist-Podcasts.

    • 4,1 (998)
    • ACTUS DU JOUR

  • Take a seat at the table and learn about the biggest stories in financial markets, the economy and business. Each week our editors and correspondents explore how economics influences the world we live in and share their insights across a range of topics. From inflation and recession risk to all things crypto and even the commercial success of K-pop, we have you covered. Published every Thursday. If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription. For more information about Economist Podcasts+, including how to get access, please visit our FAQs page at https://myaccount.economist.com/s/article/What-is-Economist-Podcasts.

    • 4,3 (903)
    • ACTUALITÉ ÉCONOMIQUE

  • Checks and Balance unlocks American politics by taking a big theme each week and digging into the data, the ideas, and the history shaping the country. Join John Prideaux, Charlotte Howard, Idrees Kahloon and Jon Fasman as they talk to politicians, pollsters, academics and people across the country about the great experiment of American democracy. Published every Friday. If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription. For more information about Economist Podcasts+, including how to get access, please visit our FAQs page here https://myaccount.economist.com/s/article/What-is-Economist-Podcasts.

    • 4,5 (1390)
    • POLITIQUE

Subscribe via The Economist app for podcast access

Afficher la FAQ sur les abonnements

Hôtes et personnes invitées

4,7
sur 5
115 notes

À propos

The Economist unlocks the science, data and politics behind the most ambitious inoculation programme the world has ever seen. Alok Jha, The Economist’s science correspondent, hosts with Natasha Loder, our health-policy editor. Each week our reporters and data journalists join them in conversation, along with scientists around the world. Sign up for Economist Podcasts+ at www.economist.com/podcastsplus If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription.

Informations

  • Chaîne
    The Economist
  • Création
    The Economist
  • Années d’activité
    2 k
  • Épisodes
    21
  • Classification
    Tous publics
  • Copyright
    Copyright © The Economist Newspaper Limited 2023. All rights reserved.
  • Site web de l’émission
    The Jab from The Economist
  • Fournisseur
    The Economist Newspaper Limited

Plus de contenus par The Economist

Vous aimeriez peut‑être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Recevez les dernières actualités sur cette émission

Connectez‑vous ou inscrivez‑vous pour suivre des émissions, enregistrer des épisodes et recevoir les dernières actualités.
Choisissez un pays ou une région

Afrique, Moyen‑Orient et Inde

Asie‑Pacifique

Europe

Amérique latine et Caraïbes

États‑Unis et Canada